Cervical cancer (CC) is the 4th most common female cancer globally, claiming more than 300,000 women’s lives in 2018.1 In Hong Kong, the incidence of CC remained high at around 7 per 100,000 women in 2019, which was still below the World Health Organization’s (WHO) target of fewer than 4 per 100,000

Human papillomavirus (HPV) is the most common sexually transmitted infection. In total, more than 40 types of HPV can be transmitted through direct sexual contact, including those types classified as high risk for the development of cervical cancer.¹

Venous thromboembolism (VTE), which includes deep-vein thrombosis and pulmonary embolism, is an important cause of morbidity and mortality amongst patients with cancer.¹ The American Society of Clinical Oncology (ASCO) first